Literature DB >> 12671525

Study of circadian melatonin secretion pattern at different stages of Parkinson's disease.

R Bordet1, D Devos, S Brique, Y Touitou, J D Guieu, C Libersa, A Destée.   

Abstract

To explore changes in melatonin secretion patterns and biologic rhythms in Parkinson's disease patients with or without levodopa-related motor complications (LDRMCs), the authors investigated, in an observational study, circadian rhythms of central temperature, motor activity, plasma cortisol, and melatonin in three groups: de novo untreated patients (group I), patients treated with levodopa + dopamine agonist and without LDRMCs (group II), and patients treated with levodopa + dopamine agonist and with LDRMCs (group III). There were no differences among the three groups for the rhythm of temperature, motor activity, or plasma cortisol. There was a significant (p < 0.05) phase advance in plasma melatonin secretion in patients receiving a dopaminergic treatment compared with untreated patients. The daytime area under the curve (AUC) was increased significantly in group III, and the nighttime AUC-to-daytime AUC ratio of melatonin secretion decreased significantly in group III, suggesting that the nychthemeral pattern of melatonin secretion was changed in patients with LDRMCs. Comparison of the three groups suggests a slight but insignificant phase advance and amplitude decrease of circadian melatonin secretion related to both evolution and treatment of Parkinson's disease. Despite the lack of a global desynchronization in other circadian biologic rhythms, the circadian secretion pattern of melatonin is modified in patients with LDRMCs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12671525     DOI: 10.1097/00002826-200303000-00005

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  46 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

2.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

3.  Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.

Authors:  Camila Andrade Mendes Medeiros; Pedro Felipe Carvalhedo de Bruin; Lívia Ariane Lopes; Maria Cecília Magalhães; Maria de Lourdes Seabra; Veralice Meireles Sales de Bruin
Journal:  J Neurol       Date:  2007-04-03       Impact factor: 4.849

Review 4.  Aging, circadian rhythms and depressive disorders: a review.

Authors:  Inês Campos Costa; Hugo Nogueira Carvalho; Lia Fernandes
Journal:  Am J Neurodegener Dis       Date:  2013-11-29

5.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

Review 6.  'The clocks that time us'--circadian rhythms in neurodegenerative disorders.

Authors:  Aleksandar Videnovic; Alpar S Lazar; Roger A Barker; Sebastiaan Overeem
Journal:  Nat Rev Neurol       Date:  2014-11-11       Impact factor: 42.937

Review 7.  Association between circadian rhythms and neurodegenerative diseases.

Authors:  Yue Leng; Erik S Musiek; Kun Hu; Francesco P Cappuccio; Kristine Yaffe
Journal:  Lancet Neurol       Date:  2019-02-12       Impact factor: 44.182

8.  Beneficial Effect of Melatonin on Motor and Memory Disturbances in 6-OHDA-Lesioned Rats.

Authors:  Lyubka Tancheva; Maria Lazarova; Luciano Saso; Reni Kalfin; Miroslava Stefanova; Diamara Uzunova; Atanas G Atanasov
Journal:  J Mol Neurosci       Date:  2021-01-05       Impact factor: 3.444

Review 9.  Circadian and sleep disorders in Parkinson's disease.

Authors:  Aleksandar Videnovic; Diego Golombek
Journal:  Exp Neurol       Date:  2012-08-23       Impact factor: 5.330

Review 10.  Sleep as a Therapeutic Target in the Aging Brain.

Authors:  Thierno M Bah; James Goodman; Jeffrey J Iliff
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.